Allergen Immunotherapy

Tolly Epstein, MD, MS
University of Cincinnati School of Medicine

Tolly Epstein


Dear Colleagues,

Allergen immunotherapy is still the only preventative and disease-modifying therapy for aeroallergen related atopic diseases, including allergic rhinitis, asthma, and atopic dermatitis, as well as for life-threatening venom allergy. The application of immunotherapy to treat these extremely common allergic diseases remains a cornerstone of the Allergy & Immunology specialty across the globe. Although immunotherapy has been widely used for over 100 years, there is much left to learn regarding mechanisms of action,  appropriate choice of allergens, delivery systems, dosing strategies, use of adjuvants, patient selection,  optimal safety measures and other topics related to immunotherapy. In addition to conventional forms of subcutaneous and sublingual immunotherapy, novel forms of immunotherapy are likely to gain acceptance in coming years. More widespread use of component based analytics to formulate immunotherapy prescriptions is also expected. 

This section is intended to provide an avenue to share original research, review articles, and meta-analyses summarizing advancements in allergen immunotherapy across the world. 

Tolly Epstein


About Tolly Epstein

Dr. Tolly Epstein, MD, MS is an Adjunct Assistant Professor of Medicine at the University of Cincinnati School of Medicine, Division of Immunology, Allergy, & Rheumatology, and a full-time private practitioner in Allergy & Immunology at Allergy Partners of Central Indiana in Indianapolis, Indiana. She also serves as adjunct faculty at Marian University in Indianapolis and volunteer faculty at Indiana University School of Medicine.

Dr. Epstein graduated in the top 1% of her class at Indiana University with a Bachelor of Science in Biology, a Bachelor of the Arts in Spanish, and a minor in English. She attended Indiana University School of Medicine, and received the Mariellen Dentino scholarship award for academic achievement in her first year of medical school. She completed an Internal medicine residency at Washington University School of Medicine/Barnes-Jewish hospital in St. Louis, Missouri, and Allergy/Immunology fellowship at University of Cincinnati School of Medicine. During her fellowship she also completed a Master’s degree in Clinical & Translational Research. 

She has served as the co-director of the National Immunotherapy Surveillance Study of North America, sponsored by the American Academy of Allergy, Asthma, & Immunology (AAAAI) and the American College of Allergy, Asthma, & Immunology since 2008. She is the immediate past chair of the Immunotherapy and Diagnostics Committee, and the current secretary of the Immunotherapy, Rhinitis, Sinusitis, and Ocular Diseases (IRSO) interest section for the AAAAI. She is also a past chair of the Asthma and Allergic Diseases in Older Adults Committee for the AAAAI, and has conducted research related to the impact of air pollutants on asthma in older adults. Dr. Epstein has published more than 25 peer-reviewed original articles related to her research, which in recent years has primarily focused on Allergen Immunotherapy.